Alternative splicing programs in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Initial antiandrogenic therapies are often overcome by treatment-resistant PCa.
• Cancerous cells exhibit genetic and phenotypic heterogeneity, complicating treatment.

Purpose of the Study:

• To review the role of alternative splicing in prostate cancer (PCa) biology.
• To highlight key genes and their alternatively spliced variants in PCa.
• To explore the potential of alternative splicing as a diagnostic and therapeutic target.

Main Methods:

• Literature review of studies on alternative splicing in prostate cancer.
• Analysis of gene expression and protein isoform data.
• Discussion of clinical implications of alternative splicing findings.

Main Results:

• Alternative splicing contributes significantly to PCa's genetic and phenotypic heterogeneity.
• Key genes, including the androgen receptor and cyclin D1, produce functionally distinct protein isoforms via alternative splicing.
• Aberrant splicing patterns are observed in both normal and cancerous prostate cells.

Conclusions:

• Alternative splicing is a critical mechanism driving prostate cancer progression and therapeutic resistance.
• Targeting alternative splicing pathways presents a promising avenue for novel PCa diagnostics and therapeutics.
• Further research into PCa splicing variants can improve patient outcomes.